BACKGROUND: Mucopolysaccharidosis type II (MPSII), also known as Hunter syndrome, is an X-linked disorder caused by mutations in the iduronate 2 sulfatase (IDS) gene. This enzyme catalyzes the initial step in the catabolism of heparan sulfate and dermatan sulfate; thus, its deficiency leads to the accumulation of these glycosaminoglycans. MPS II has significant allelic heterogeneity, making the establishment of genotype-phenotype correlations difficult. This study assessed clinical features in combination with deep genotyping of a group of Colombian patients with MPS II and attempted to establish a degree of genotype-phenotype correlation by employing bioinformatic tools. METHODS: Eighteen patients were included in this study, 11% of whom were non-neuronopathic, and the other 89% were neuronopathic. Samples were all analyzed using three molecular methodologies: MLPA, direct exon sequencing, and RFLP analysis. RESULTS: A total of 13 mutations were identified, 6 of which were novel (c.548_564dup16, c.477insT, c.595_607del12, c. 549_562del13, c.182delC, and a complete deletion of exon 7). The frequency of common mutations (R468Q, Q465X, K347Q, K236N, S71N, R88H, and a conversion phenomenon) was 53.85%. The S71N mutation was frequent among the attenuated phenotype, while private frameshift mutations and rearrangements were seen in patients with severe phenotypes. Molecular docking was performed on the wild-type and mutant IDS proteins, which revealed changes in the enzyme-substrate interaction for the mutant IDS. CONCLUSION: The frequency of novel mutations (46.15%) is similar to what has been reported elsewhere. The use of bioinformatic tools showed differences in enzyme-substrate interactions. Studies with larger groups of patients are needed.
BACKGROUND:Mucopolysaccharidosis type II (MPSII), also known as Hunter syndrome, is an X-linked disorder caused by mutations in the iduronate 2 sulfatase (IDS) gene. This enzyme catalyzes the initial step in the catabolism of heparan sulfate and dermatan sulfate; thus, its deficiency leads to the accumulation of these glycosaminoglycans. MPS II has significant allelic heterogeneity, making the establishment of genotype-phenotype correlations difficult. This study assessed clinical features in combination with deep genotyping of a group of Colombian patients with MPS II and attempted to establish a degree of genotype-phenotype correlation by employing bioinformatic tools. METHODS: Eighteen patients were included in this study, 11% of whom were non-neuronopathic, and the other 89% were neuronopathic. Samples were all analyzed using three molecular methodologies: MLPA, direct exon sequencing, and RFLP analysis. RESULTS: A total of 13 mutations were identified, 6 of which were novel (c.548_564dup16, c.477insT, c.595_607del12, c. 549_562del13, c.182delC, and a complete deletion of exon 7). The frequency of common mutations (R468Q, Q465X, K347Q, K236N, S71N, R88H, and a conversion phenomenon) was 53.85%. The S71N mutation was frequent among the attenuated phenotype, while private frameshift mutations and rearrangements were seen in patients with severe phenotypes. Molecular docking was performed on the wild-type and mutant IDS proteins, which revealed changes in the enzyme-substrate interaction for the mutant IDS. CONCLUSION: The frequency of novel mutations (46.15%) is similar to what has been reported elsewhere. The use of bioinformatic tools showed differences in enzyme-substrate interactions. Studies with larger groups of patients are needed.
Authors: A C Brusius-Facchin; I V D Schwartz; C Zimmer; M G Ribeiro; A X Acosta; D Horovitz; I L Monlleó; M I B Fontes; A Fett-Conte; R P Oliveira Sobrinho; A R Duarte; R Boy; P Mabe; M Ascurra; M de Michelena; K L Tylee; G T N Besley; M C V Garreton; R Giugliani; S Leistner-Segal Journal: Mol Genet Metab Date: 2013-09-01 Impact factor: 4.797
Authors: P J Wilson; C P Morris; D S Anson; T Occhiodoro; J Bielicki; P R Clements; J J Hopwood Journal: Proc Natl Acad Sci U S A Date: 1990-11 Impact factor: 11.205
Authors: K Isogai; K Sukegawa; S Tomatsu; T Fukao; X Q Song; Y Yamada; S Fukuda; T Orii; N Kondo Journal: J Inherit Metab Dis Date: 1998-02 Impact factor: 4.982
Authors: K Sukegawa-Hayasaka; Z Kato; H Nakamura; S Tomatsu; T Fukao; K Kuwata; T Orii; N Kondo Journal: J Inherit Metab Dis Date: 2006-11-07 Impact factor: 4.982
Authors: J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman Journal: Eur J Pediatr Date: 2007-11-23 Impact factor: 3.183
Authors: Mary Anne D Chiong; Daffodil M Canson; Mary Ann R Abacan; Melissa Mae P Baluyot; Cynthia P Cordero; Catherine Lynn T Silao Journal: Orphanet J Rare Dis Date: 2017-01-11 Impact factor: 4.123
Authors: L Chkioua; O Grissa; N Leban; M Gribaa; H Boudabous; H Ben Turkia; S Ferchichi; N Tebib; S Laradi Journal: BMC Med Genet Date: 2020-05-24 Impact factor: 2.103
Authors: Caio Perez Gomes; Maryana Mara Marins; Fabiana Louise Motta; Sandra Obikawa Kyosen; Marco Antonio Curiati; Vânia D'Almeida; Ana Maria Martins; João Bosco Pesquero Journal: Front Genet Date: 2020-03-18 Impact factor: 4.599